Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046584 | 0.81 | TDP1 (0.47) | JMJD6KMT2ATDP1SLC6A3SLC6A2 | |
| SCHEMBL26511197 | 0.77 | LMNA (0.49) | JMJD6KMT2ATDP1SLC6A3SLC6A2 | |
| SCHEMBL30199385 | 0.77 | HTR2C (0.51) | OPRM1KMT2ASLC6A4HTR2CTMEM97 | |
| SCHEMBL20046582 | 0.75 | CRBN (0.45) | — | |
| SCHEMBL30199651 | 0.69 | HTR2C (0.53) | KMT2ACYP2C9SLC6A4HTR2CALDH1A1 | |
| SCHEMBL12542345 | 0.69 | SGPL1 (0.54) | KMT2ASLC6A3LMNACHRNB2CHRNA7 | |
| SCHEMBL20305861 | 0.69 | TDP1 (0.64) | JMJD6KMT2ATDP1SLC6A3SLC6A2 | |
| SCHEMBL21336724 | 0.69 | HDAC1 (0.51) | KMT2ATDP1SLC6A3LMNACHRNB2 | |
| SCHEMBL24944807 | 0.68 | P4HTM (0.50) | CHRM4 | |
| SCHEMBL21336665 | 0.68 | KMT2A (0.48) | KMT2ATDP1SLC6A3SLC6A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | JMJD6 449/4885OPRM1 1832/4885KMT2A 1463/4885 |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | JMJD6 464/4885OPRM1 1885/4885KMT2A 1478/4885 |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | JMJD6 464/4885OPRM1 1885/4885KMT2A 1478/4885 |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | JMJD6 449/4885OPRM1 1832/4885KMT2A 1463/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | JMJD6 464/4885OPRM1 1885/4885KMT2A 1478/4885 |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | JMJD6 464/4885OPRM1 1885/4885KMT2A 1478/4885 |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | JMJD6 449/4885OPRM1 1832/4885KMT2A 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.